Vera Therapeutics names new Chief Regulatory Officer

Vera Therapeutics, Inc. is changing its regulatory leadership.

Accepted by SEC EDGAR 07/09/2026 - 08:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Vera Therapeutics, Inc. is changing its regulatory leadership. Effective August 3, 2026, Nancy Bowman, M.D., Ph.D. will become the company’s Chief Regulatory Officer. On the same date, current Chief Regulatory Officer William Turner will step down from that role and move into a new position as Special Advisor for Regulatory Affairs.

The company disclosed this leadership transition under the category covering departures and appointments of certain officers.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Effective date of role changes: August 3, 2026 Announcement date: July 9, 2026 Par value per share: $0.001 per share

3 metrics

Effective date of role changes August 3, 2026 Date when CRO and advisor roles take effect

Announcement date July 9, 2026 Date company announced the officer transition

Par value per share $0.001 per share Class A common stock par value

Key Terms

Chief Regulatory Officer, Special Advisor for Regulatory Affairs, Emerging growth company, Section 12(b) of the Act

4 terms

Chief Regulatory Officer financial

"will succeed Mr. Turner as the Company’s Chief Regulatory Officer, effective as of August 3, 2026"

Special Advisor for Regulatory Affairs financial

"will transition to the role of Special Advisor for Regulatory Affairs, effective as of August 3, 2026"

Emerging growth company regulatory

"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Section 12(b) of the Act regulatory

"Securities registered pursuant to Section 12(b) of the Act"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Vera Therapeutics (VERA) announce in this 8-K?

Vera Therapeutics announced a regulatory leadership transition. William Turner will leave the Chief Regulatory Officer role and become Special Advisor for Regulatory Affairs, while Nancy Bowman, M.D., Ph.D., will assume the Chief Regulatory Officer position effective August 3, 2026.

Who is becoming Chief Regulatory Officer at Vera Therapeutics (VERA)?

Nancy Bowman, M.D., Ph.D., will become Chief Regulatory Officer at Vera Therapeutics. She is scheduled to assume the role effective August 3, 2026, succeeding William Turner, who will move to a Special Advisor for Regulatory Affairs position on the same date.

What happens to current Chief Regulatory Officer William Turner at Vera Therapeutics (VERA)?

William Turner will transition from Chief Regulatory Officer to Special Advisor for Regulatory Affairs. This change takes effect August 3, 2026, allowing him to continue contributing regulatory expertise to Vera Therapeutics while Nancy Bowman, M.D., Ph.D., takes over the Chief Regulatory Officer role.

When does the officer transition at Vera Therapeutics (VERA) become effective?

The officer transition becomes effective on August 3, 2026. On that date, Nancy Bowman, M.D., Ph.D., will assume the Chief Regulatory Officer role, and William Turner will move into the position of Special Advisor for Regulatory Affairs at Vera Therapeutics.

Under which item did Vera Therapeutics (VERA) disclose this management change?

The management change was disclosed under Item 5.02, which covers departures and appointments of directors and certain officers. This item is used when companies report executive changes such as role transitions, promotions, or departures that may be important to shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000183182800018318282026-07-092026-07-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 09, 2026

Vera Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40407	81-2744449
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2000 Sierra Point Parkway, Suite 1200
Brisbane, California				94005
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 770-0077

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A common stock, $0.001 par value per share		VERA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 9, 2026, Vera Therapeutics, Inc. (the “Company”) announced that William Turner will no longer serve as the Company’s Chief Regulatory Officer and will transition to the role of Special Advisor for Regulatory Affairs, effective as of August 3, 2026. Nancy Bowman, M.D., Ph.D., will succeed Mr. Turner as the Company’s Chief Regulatory Officer, effective as of August 3, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Vera Therapeutics, Inc.
Date:	July 9, 2026	By:	/s/ Marshall Fordyce
			Marshall Fordyce, M.D. Chief Executive Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 24.4 KB